Sam is a trained cell biologist with a background in stem cell biology and regulation of cell fate decisions. In partnership with AstraZeneca, Sam completed his PhD in stem cell epigenetics at UCL Cancer Institute in 2022. Here, he demonstrated a role for pan-cancer target Stag1 in organising DNA into higher order structures. Continuing research of Stag proteins, Sam completed a post-doctoral fellowship, where he identified a novel function for the Cancer Testis Antigen, Stag3, in regulating post-transcriptional gene expression.
Sign up to view 0 direct reports
Get started